ViroStatics srl
ViroStatics is a privately held small pharmaceutical company dedicated to advancing medical research and providing top-tier testing services. The company focuses on discovering and developing novel compounds for cancer and viral diseases, with a strong emphasis on kinase targeted inhibitors. It also offers contract testing services for respiratory viruses, including SARS-CoV-2, and employs advanced assays to elucidate mechanisms of action. ViroStatics has a robust pipeline of proprietary compounds, including the clinical candidate Myrtleciclib, and collaborates on various research projects supported by grants and European programs. The company is committed to innovation, scientific excellence, and addressing unmet medical needs in oncology and virology.
Industries
Nr. of Employees
small (1-50)
ViroStatics srl
Viale Umberto I, 46 07100 Sassari (SS), Italy
Patents
Products
Lead oral CDK4/6/9 inhibitor candidate (advanced preclinical)
An orally bioavailable small-molecule CDK4/6/9 inhibitor developed to inhibit Myc-driven cancer proliferation; demonstrated in vitro and in vivo efficacy, favorable toxicity profile in rodents and non-rodents, and described as API GMP-ready with IND-enabling work planned.
Lead oral CDK4/6/9 inhibitor candidate (advanced preclinical)
An orally bioavailable small-molecule CDK4/6/9 inhibitor developed to inhibit Myc-driven cancer proliferation; demonstrated in vitro and in vivo efficacy, favorable toxicity profile in rodents and non-rodents, and described as API GMP-ready with IND-enabling work planned.
Services
Cell-based evaluation of antiviral efficacy, cytotoxicity determination, IC50/CC50 estimation and viral replication assays for drugs, biologics or devices; capability to handle current variants.
Aerosolization model and bioaerosol exposure system to test nebulised treatments, inhalers, disinfectants and devices for virucidal activity in aerosol form.
Design and execution of mechanism-of-action assays and combination studies (antiproliferative and antiviral) including cell cycle and synergy analyses.
ELISPOT and PHPC assays for detection of effector and memory T cell responses; support for immunogenicity endpoints in early-phase clinical trials.
Primary cell and tumor cell line toxicity profiling, apoptosis assays and mitochondrial toxicity testing to characterize safety liabilities.
Screening and hit validation services supported by proteomics and systems-biology analyses to identify and characterize lead compounds.
Cell-based evaluation of antiviral efficacy, cytotoxicity determination, IC50/CC50 estimation and viral replication assays for drugs, biologics or devices; capability to handle current variants.
Aerosolization model and bioaerosol exposure system to test nebulised treatments, inhalers, disinfectants and devices for virucidal activity in aerosol form.
Design and execution of mechanism-of-action assays and combination studies (antiproliferative and antiviral) including cell cycle and synergy analyses.
ELISPOT and PHPC assays for detection of effector and memory T cell responses; support for immunogenicity endpoints in early-phase clinical trials.
Primary cell and tumor cell line toxicity profiling, apoptosis assays and mitochondrial toxicity testing to characterize safety liabilities.
Screening and hit validation services supported by proteomics and systems-biology analyses to identify and characterize lead compounds.
Expertise Areas
- Antiviral drug development
- Oncology small-molecule discovery (CDK inhibitors)
- Preclinical pharmacology and toxicology
- BSL-3 virology testing and containment
Key Technologies
- Flow cytometry
- ELISPOT and PHPC immunoassays
- High-throughput screening (HTS)
- Proteomics and systems-biology analysis
News & Updates
The mid-term meeting highlighted key achievements including the identification of four preclinical candidates with broad-spectrum antiviral activity and the discovery of hundreds of antiviral hits.
A networking event for scientists and stakeholders to discuss emerging infectious diseases and One Health approaches.
Recognition for its commitment to health protection, environment, sustainability, and social integration.
The mid-term meeting highlighted key achievements including the identification of four preclinical candidates with broad-spectrum antiviral activity and the discovery of hundreds of antiviral hits.
A networking event for scientists and stakeholders to discuss emerging infectious diseases and One Health approaches.
Recognition for its commitment to health protection, environment, sustainability, and social integration.